Provenance du réseau au premier degré de Willem Hazenberg
Entité | Type d'entité | Industrie | |
---|---|---|---|
Biogeneration Management BV
Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.
6
| Subsidiary | Investment Managers | 6 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Willem Hazenberg via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
University of Utrecht | College/University | Doctorate Degree Graduate Degree | |
Cristal Delivery BV
Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Mellon Medical BV
Mellon Medical BV Medical SpecialtiesHealth Technology Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
Sirius Medical Systems BV
Sirius Medical Systems BV Medical SpecialtiesHealth Technology Sirius Medical BV engages in medical industry. The firm focuses on developing medical devices for oncological surgery. The company was founded by Hubert Martens and Bram Schermers and is headquartered in Eindhoven, the Netherlands. | Medical Specialties | Director/Board Member | |
BMEYE BV
BMEYE BV Electronic Equipment/InstrumentsElectronic Technology BMEYE BV operates as a non-invasive cardiovascular monitoring company. The firm manufactures and distributes non-invasive technology, hemodynamic monitoring equipment and related medical devices. It offers finger arterial pressure and cardiac output technologies. The company was founded in April 2005 and is headquartered in Amsterdam, the Netherlands. | Electronic Equipment/Instruments | President | |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer | |
Ventinova Medical BV
Ventinova Medical BV Medical SpecialtiesHealth Technology Ventinova Medical BV develops and markets products in the field of anesthesiology. Its products include Ventrain, Cricath, and Ventrain Emergency Kit. The company was founded by Dirk van Asseldonk in 2013 and is headquartered in Eindhoven, Netherlands. | Medical Specialties | Director/Board Member | |
SurgVision BV
SurgVision BV Medical SpecialtiesHealth Technology SurgVision BV provides optical imaging camera systems. It develops integrated optical imaging platforms, including camera, software and target specific tracer, for specific disease areas like breast cancer surgery. The company was founded by Vasilis Ntziachristos and Ton van den Hoven in 2011 and is headquartered in 't Harde, the Netherlands. | Medical Specialties | Chairman | |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Chief Executive Officer | |
University of Leiden | College/University | Undergraduate Degree | |
AVANTIUM N.V. | Industrial Machinery | Corporate Officer/Principal | |
TigaTx, Inc.
TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Biotechnology | Director/Board Member | |
University of Twente | College/University | Graduate Degree | |
INSEAD | College/University | Masters Business Admin | |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member | |
Dunad Therapeutics Ltd.
Dunad Therapeutics Ltd. BiotechnologyHealth Technology Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Director of Finance/CFO | |
Oxitope Pharma BV
Oxitope Pharma BV Pharmaceuticals: MajorHealth Technology Oxitope Pharma BV is a Dutch pharmaceutical start-up founded in 2020 that focuses on discovering and developing medicine for the treatment of inflammatory and cardiovascular diseases caused by oxidative stress. The company is based in Naarden, Netherlands. The Dutch company takes a different approach to the diagnosis and treatment of these diseases by preventing, halting, or reversing acute and chronic diseases driven by oxidized phospholipids. Oxitope Pharma's goal is to enable people to live long and healthy lives. The CEO is John Montana. | Pharmaceuticals: Major | Director/Board Member | |
Dualyx NV
Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Miscellaneous Commercial Services | Director/Board Member | |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
Delft University of Technology | College/University | Graduate Degree | |
Dr. Reddy's Research & Development BV
Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Pharmaceuticals: Major | Founder | |
Crossbeta Biosciences BV
Crossbeta Biosciences BV BiotechnologyHealth Technology Crossbeta Biosciences BV develops drug discovery programs in the area of misfolded protein diseases. It specializes in alzheimer's disease drug development and drug discovery platform services. The company was founded by Martijn Gebbink and Barend Bouma in 2005 and is headquartered in Utrecht, the Netherlands. | Biotechnology | Chairman | |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Polpharma Biologics Utrecht BV
Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
TigaTx BV
TigaTx BV Miscellaneous Commercial ServicesCommercial Services TigaTx BV is a Dutch company that provides research and development in the field of health nutrition. The company is based in Utrecht, the Netherlands. The company was founded in 2020 by Jeanette Leusen. | Miscellaneous Commercial Services | Director/Board Member | |
Stichting Publieke Private Samenwerking Versterking
Stichting Publieke Private Samenwerking Versterking Investment Trusts/Mutual FundsMiscellaneous Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Biotechnology | Director/Board Member | |
Escalier Biosciences BV
Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member | |
Genase Therapeutics BV
Genase Therapeutics BV Pharmaceuticals: MajorHealth Technology Genase Therapeutics BV develops therapeutic products to treat solid tumors. The company is based in Oss, Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Forbion Capital Fund III Coöperatief UA
Forbion Capital Fund III Coöperatief UA Financial ConglomeratesFinance Part of Forbion Capital Partners Management Holding BV, Forbion Capital Fund III Coöperatief UA is a company based in Naarden, Netherlands. The Dutch company provides investment services. | Financial Conglomerates | Director/Board Member |
Statistiques
Internationale
Pays-Bas | 33 |
Etats-Unis | 4 |
Belgique | 3 |
France | 2 |
Royaume-Uni | 2 |
Sectorielle
Health Technology | 24 |
Consumer Services | 6 |
Commercial Services | 5 |
Finance | 3 |
Electronic Technology | 2 |
Opérationnelle
Director/Board Member | 23 |
Private Equity Investor | 5 |
Corporate Officer/Principal | 5 |
Chief Executive Officer | 4 |
Chairman | 3 |
Relations les plus connectées
- Bourse
- Insiders
- Willem Hazenberg
- Connexions Sociétés